SCHEMBL24075313

SCHEMBL24075313

Cc1cc2nc(-c3ccc(-c4ccccc4)cc3)[nH]c2cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 1/20 0.61
METAP2 P50579 1/20 0.59
METAP1 P53582 1/20 0.59
CBFB Q13951 1/20 0.59
GUSB P08236 12/20 0.59
SCD O00767 1/20 0.57
ADORA3 P0DMS8 1/20 0.56
DGAT1 O75907 1/20 0.56
KCNH2 Q12809 1/20 0.56
NPC1 O15118 2/20 0.56
GAA P10253 2/20 0.56
RAB9A P51151 2/20 0.56
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
GLA P06280 1/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 1/20 0.55
HTT P42858 1/20 0.55
GFER P55789 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337332 0.97 METAP2 (0.62) HPSEMETAP2METAP1CBFBGUSB
SCHEMBL903717 0.88 NPC1 (0.66) SCDDGAT1KCNH2NPC1GAA
SCHEMBL25722414 0.86 HPSE (0.64) HPSEMETAP2METAP1CBFBGUSB
SCHEMBL24075251 0.84 METAP2 (0.56) HPSEMETAP2METAP1CBFBGUSB
SCHEMBL3333916 0.83 GUSB (0.79) HPSEGUSBNPC1GAARAB9A
SCHEMBL6325549 0.83 ALDH1A1 (0.68) HPSEGUSBNPC1GAARAB9A
SCHEMBL7393557 0.83 GUSB (0.79) HPSEGUSBSCDDGAT1KCNH2
SCHEMBL28179657 0.83 HPSE (0.60) HPSEMETAP2METAP1CBFBGUSB
SCHEMBL3132123 0.82 NPC1 (0.68) SCDDGAT1KCNH2NPC1GAA
Hydrochloric Acid SCHEMBL10736606 0.82 GUSB (0.77) HPSEGUSBSCDDGAT1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 US disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 US disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 US disclosed
WO-2021242790-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF EPHX1, EPHX2, NCEH1 HPSE 105/4885METAP2 622/4885METAP1 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.